ArticleBlood cancer journal2021

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.

Jacob P Laubach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.